Work

Supplementary Figure 4 from PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN

Year: 2023

Type: supplementary-materials

Abstract: Immune cell density by PD-L1 expression

DOI: 10.1158/1078-0432.22472072.v1

Authors: Abdallah Flaifel, Wanling Xie, David A. Braun, Miriam Ficial, Ziad Bakouny, Amin H. Nassar, Rebecca B. Jennings, Bernard Escudier, Daniel J. George, Robert J. Motzer, Michael J. Morris, Thomas Powles, Evelyn Wang, Ying Huang, Gordon J. Freeman, Toni K. Choueiri, Sabina Signoretti

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361935494

Cites:

Cited by:

Related to: 10